Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

Conditions

• Plaque Psoriasis

Eligibility Criteria

Sex

ALL

Age

12 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Roflumilast foam 0.3% — DRUG
  experimental
• Vehicle foam — DRUG
  experimental

Study Details

This study will assess the safety and efficacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with scalp and body psoriasis

Key Dates

Start date

Jan 13, 2020

Status verified

Oct 2022

Primary completion

Sep 23, 2020

Completion

Sep 25, 2020

Study Design

Enrollment

304 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: ARQ-154 foam 0.3%
  active
• Placebo Comparator: ARQ foam VehicleRQ-154 foam Vehicle
  placebo

Primary Outcome Measure

Number of Participants Achieving Success in the Scalp Investigator Global Assessment (S-IGA) Scale [ Time Frame: Week 8 ]

Locations (31)

Find similar trials in Rogers, AR

Related Studies

• Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
  EARLY_PHASE1 · Recruiting · Wright State University · Fairborn, Ohio
• Understanding Participation Habits Among Plaque Psoriasis Patients
  Not Yet Recruiting · Power Life Sciences Inc. · San Francisco, California
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
  PHASE3 · Recruiting · Bristol-Myers Squibb · Birmingham, Alabama
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis
  PHASE1 · Recruiting · Ascletis Pharma (China) Co., Limited · Miami, Florida